Pacira BioSciences, Inc. (PCRX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Pacira BioSciences, Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 26.40 $ — 90% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 2.9% failed
- More than 10% revenue growth is expected for the coming year 8.3% failed
- Share count grows by less than 3% a year -1.1% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 22.4% failed
- Gross margin at 40% or higher and without meaningful erosion 79.4% passed
- Goodwill from acquisitions does not grow faster than revenue 1.6% passed
- Net debt below twice EBITDA 1.8 x EBITDA passed
- Operating cash flow covers the profits of the last three years 547 m passed
- Return on capital at 15% or higher, or up versus two years ago 2.9% failed
- Insiders hold at least 10% or are net buyers 1.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 12.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.88 | 2.74 – 2.98 | 768 | 8.6% | 6 |
| 12/31/2027 | 3.65 | 3.18 – 4.01 | 831 | 26.8% | 6 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.27 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.33 | -31.50 | 187 | 3.30 | 8.60 | 33 | 31 |
| 2025: Q1 | 0.10 | -39.90 | 169 | 1.10 | 2.80 | 36 | 27 |
| 2025: Q2 | -0.11 | -128.50 | 181 | 1.70 | -2.70 | 12 | 9 |
| 2025: Q3 | 0.12 | – | 180 | 6.50 | 3.00 | 61 | 57 |
| 2025: Q4 | 0.04 | -88.40 | 197 | 5.10 | 0.80 | 44 | 44 |
| 2026: Q1 | 0.07 | -31.10 | 177 | 5.00 | 1.60 | 26 | 23 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 276 | -32 | -38 | -1.02 | 33 | 219 | 391 |
| 2017 | 287 | -25 | -43 | -1.07 | 18 | 279 | 628 |
| 2018 | 337 | 16 | 0 | -0.01 | 49 | 321 | 689 |
| 2019 | 421 | 10 | -11 | -0.27 | 71 | 355 | 831 |
| 2020 | 430 | 46 | 146 | 3.33 | 77 | 620 | 1,275 |
| 2021 | 542 | 90 | 42 | 0.92 | 126 | 730 | 2,075 |
| 2022 | 667 | 60 | 16 | 0.34 | 145 | 775 | 1,681 |
| 2023 | 675 | 88 | 42 | 0.81 | 155 | 870 | 1,574 |
| 2024 | 701 | -73 | -100 | -2.15 | 189 | 778 | 1,554 |
| 2025 | 726 | 33 | 7 | 0.16 | 152 | 693 | 1,265 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Pacira BioSciences, Inc. beschäftigt sich mit der Entwicklung, Herstellung, Vermarktung, dem Vertrieb und dem Verkauf von nicht-opioidbasierten Schmerzmanagement- und regenerativen Gesundheitslösungen für medizinisches Fachpersonal in den USA.
| Employees | 825 |
|---|---|
| Headquarters | Brisbane, CA |
| Address | 2000 Sierra Point Parkway, 94005 Brisbane, United States |
| Phone | 650 242 8052 |
| Website | pacira.com |
| IPO Date | 3. Feb 2011 |
| ISIN | US6951271005 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Frank D. Lee | CEO & Director | 1968 |
| Shawn M. Cross | Chief Financial Officer | 1968 |
| Kristen Williams Esq., J.D. | Chief Administrative Officer & Secretary | 1974 |
| Jonathan Slonin M.D. | Chief Medical Officer | 1975 |
| Brendan P. Teehan | Chief Commercial Officer | 1969 |
| Lauren Bullaro Riker | Principal Accounting Officer & Senior VP of Finance | 1979 |
| Susan Mesco | Head of Investor Relations | – |
| Anthony Molloy III, Esq. | Chief Legal & Compliance Officer | 1974 |
| Christopher C. Young | Chief Manufacturing Officer | 1972 |
| Krys Corbett Esq. | Chief Business Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 23. Apr 2026 | Shawn Cross | CFO | Sell | 12,941 | 25.16 | 325,596 |
| 22. Apr 2026 | Shawn Cross | CFO | Sell | 1,500 | 25.01 | 37,515 |
| 21. Apr 2026 | Shawn Cross | CFO | Sell | 2,845 | 25.01 | 71,153 |
| 20. Apr 2026 | Shawn Cross | CFO | Sell | 7,714 | 25.14 | 193,930 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.